Fibroblast growth factor 23 is an independent and specific predictor of mortality in patients with heart failure and reduced ejection fractionE
Background - Strategies to improve risk prediction are of major importance in patients with heart failure (HF). Fibroblast growth factor 23 (FGF-23) is an endocrine regulator of phosphate and vitamin D homeostasis associated with an increased cardiovascular risk. We aimed to assess the prognostic ef...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
August 13, 2015
|
| In: |
Circulation. Heart failure
Year: 2015, Volume: 8, Issue: 6, Pages: 1059-1067 |
| ISSN: | 1941-3297 |
| DOI: | 10.1161/CIRCHEARTFAILURE.115.002341 |
| Online Access: | Verlag, teilw. kostenfrei, Volltext: http://dx.doi.org/10.1161/CIRCHEARTFAILURE.115.002341 Verlag, teilw. kostenfrei, Volltext: http://circheartfailure.ahajournals.org.ezproxy.medma.uni-heidelberg.de/content/8/6/1059 
|
| Author Notes: | Lorenz Koller, Marcus E. Kleber, Vincent M. Brandenburg, Georg Goliasch, Bernhard Richter, Patrick Sulzgruber, Hubert Scharnagl, Günther Silbernagel, Tanja B. Grammer, Graciela Delgado, Andreas Tomaschitz, Stefan Pilz, Rudolf Berger, Deddo Mörtl, Martin Hülsmann, Richard Pacher, Winfried März, Alexander Niessner |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1566637570 | ||
| 003 | DE-627 | ||
| 005 | 20220814051305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171221s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCHEARTFAILURE.115.002341 |2 doi | |
| 035 | |a (DE-627)1566637570 | ||
| 035 | |a (DE-576)496637576 | ||
| 035 | |a (DE-599)BSZ496637576 | ||
| 035 | |a (OCoLC)1340985517 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Koller, Lorenz |e VerfasserIn |0 (DE-588)1149297662 |0 (DE-627)1009615874 |0 (DE-576)496637118 |4 aut | |
| 245 | 1 | 0 | |a Fibroblast growth factor 23 is an independent and specific predictor of mortality in patients with heart failure and reduced ejection fractionE |c Lorenz Koller, Marcus E. Kleber, Vincent M. Brandenburg, Georg Goliasch, Bernhard Richter, Patrick Sulzgruber, Hubert Scharnagl, Günther Silbernagel, Tanja B. Grammer, Graciela Delgado, Andreas Tomaschitz, Stefan Pilz, Rudolf Berger, Deddo Mörtl, Martin Hülsmann, Richard Pacher, Winfried März, Alexander Niessner |
| 264 | 1 | |c August 13, 2015 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 21.12.2017 | ||
| 520 | |a Background - Strategies to improve risk prediction are of major importance in patients with heart failure (HF). Fibroblast growth factor 23 (FGF-23) is an endocrine regulator of phosphate and vitamin D homeostasis associated with an increased cardiovascular risk. We aimed to assess the prognostic effect of FGF-23 on mortality in HF patients with a particular focus on differences between patients with HF with preserved ejection fraction and patients with HF with reduced ejection fraction (HFrEF). Methods and Results - FGF-23 levels were measured in 980 patients with HF enrolled in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study including 511 patients with HFrEF and 469 patients with HF with preserved ejection fraction and a median follow-up time of 8.6 years. FGF-23 was additionally measured in a second cohort comprising 320 patients with advanced HFrEF. FGF-23 was independently associated with mortality with an adjusted hazard ratio per 1-SD increase of 1.30 (95% confidence interval, 1.14-1.48; P<0.001) in patients with HFrEF, whereas no such association was found in patients with HF with preserved ejection fraction (for interaction, P=0.043). External validation confirmed the significant association with mortality with an adjusted hazard ratio per 1 SD of 1.23 (95% confidence interval, 1.02-1.60; P=0.027). FGF-23 demonstrated an increased discriminatory power for mortality in addition to N-terminal pro-B-type natriuretic peptide (C-statistic: 0.59 versus 0.63) and an improvement in net reclassification index (39.6%; P<0.001). Conclusions - FGF-23 is independently associated with an increased risk of mortality in patients with HFrEF but not in those with HF with preserved ejection fraction, suggesting a different pathophysiologic role for both entities. | ||
| 650 | 4 | |a biological markers | |
| 650 | 4 | |a fibroblast growth factors | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a risk assessment | |
| 700 | 1 | |a Kleber, Marcus E. |d 1974- |e VerfasserIn |0 (DE-588)1030135177 |0 (DE-627)734830440 |0 (DE-576)377941379 |4 aut | |
| 700 | 1 | |a Grammer, Tanja B. |d 1972- |e VerfasserIn |0 (DE-588)1030134952 |0 (DE-627)734830041 |0 (DE-576)377941018 |4 aut | |
| 700 | 1 | |a Delgado Gonzales de Kleber, Graciela |d 1960- |e VerfasserIn |0 (DE-588)1070236403 |0 (DE-627)823400379 |0 (DE-576)429882386 |4 aut | |
| 700 | 1 | |a März, Winfried |d 1958- |e VerfasserIn |0 (DE-588)1027603599 |0 (DE-627)729463605 |0 (DE-576)373454635 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation. Heart failure |d Philadelphia, Pa. : Lippincott, Williams & Wilkins, 2008 |g 8(2015), 6, Seite 1059-1067 |h Online-Ressource |w (DE-627)567145719 |w (DE-600)2428100-1 |w (DE-576)299311058 |x 1941-3297 |7 nnas |a Fibroblast growth factor 23 is an independent and specific predictor of mortality in patients with heart failure and reduced ejection fractionE |
| 773 | 1 | 8 | |g volume:8 |g year:2015 |g number:6 |g pages:1059-1067 |g extent:9 |a Fibroblast growth factor 23 is an independent and specific predictor of mortality in patients with heart failure and reduced ejection fractionE |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCHEARTFAILURE.115.002341 |x Verlag |x Resolving-System |z teilw. kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://circheartfailure.ahajournals.org.ezproxy.medma.uni-heidelberg.de/content/8/6/1059 |x Verlag |z teilw. kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171221 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 1070236403 |a Delgado Gonzales de Kleber, Graciela |m 1070236403:Delgado Gonzales de Kleber, Graciela |d 60000 |d 65300 |e 60000PD1070236403 |e 65300PD1070236403 |k 0/60000/ |k 1/60000/65300/ |p 10 | ||
| 998 | |g 1030134952 |a Grammer, Tanja B. |m 1030134952:Grammer, Tanja B. |d 60000 |d 65300 |e 60000PG1030134952 |e 65300PG1030134952 |k 0/60000/ |k 1/60000/65300/ |p 9 | ||
| 998 | |g 1030135177 |a Kleber, Marcus E. |m 1030135177:Kleber, Marcus E. |d 60000 |d 61400 |e 60000PK1030135177 |e 61400PK1030135177 |k 0/60000/ |k 1/60000/61400/ |p 2 | ||
| 999 | |a KXP-PPN1566637570 |e 2990793631 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Lorenz Koller, Marcus E. Kleber, Vincent M. Brandenburg, Georg Goliasch, Bernhard Richter, Patrick Sulzgruber, Hubert Scharnagl, Günther Silbernagel, Tanja B. Grammer, Graciela Delgado, Andreas Tomaschitz, Stefan Pilz, Rudolf Berger, Deddo Mörtl, Martin Hülsmann, Richard Pacher, Winfried März, Alexander Niessner"]},"recId":"1566637570","note":["Gesehen am 21.12.2017"],"origin":[{"dateIssuedDisp":"August 13, 2015","dateIssuedKey":"2015"}],"language":["eng"],"person":[{"family":"Koller","given":"Lorenz","display":"Koller, Lorenz","role":"aut"},{"display":"Kleber, Marcus E.","role":"aut","family":"Kleber","given":"Marcus E."},{"family":"Grammer","given":"Tanja B.","display":"Grammer, Tanja B.","role":"aut"},{"display":"Delgado Gonzales de Kleber, Graciela","role":"aut","family":"Delgado Gonzales de Kleber","given":"Graciela"},{"display":"März, Winfried","role":"aut","family":"März","given":"Winfried"}],"physDesc":[{"extent":"9 S."}],"id":{"doi":["10.1161/CIRCHEARTFAILURE.115.002341"],"eki":["1566637570"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Fibroblast growth factor 23 is an independent and specific predictor of mortality in patients with heart failure and reduced ejection fractionE","title_sort":"Fibroblast growth factor 23 is an independent and specific predictor of mortality in patients with heart failure and reduced ejection fractionE"}],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"issn":["1941-3297"],"zdb":["2428100-1"],"eki":["567145719"]},"physDesc":[{"extent":"Online-Ressource"}],"part":{"issue":"6","pages":"1059-1067","text":"8(2015), 6, Seite 1059-1067","volume":"8","year":"2015","extent":"9"},"title":[{"title":"Circulation","subtitle":"an official journal of the American Heart Association","partname":"Heart failure","title_sort":"Circulation"}],"pubHistory":["1.2008 -"],"language":["eng"],"origin":[{"publisher":"Lippincott, Williams & Wilkins","dateIssuedDisp":"2008-","dateIssuedKey":"2008","publisherPlace":"Philadelphia, Pa."}],"corporate":[{"display":"American Heart Association","role":"isb"}],"recId":"567145719","titleAlt":[{"title":"Circulation / Heart failure"}],"disp":"Fibroblast growth factor 23 is an independent and specific predictor of mortality in patients with heart failure and reduced ejection fractionECirculation. Heart failure"}]} | ||
| SRT | |a KOLLERLOREFIBROBLAST1320 | ||